Fig. 6
Exosomes containing miR-128-3p sensitized CRC cells to oxaliplatin by targeting to Bmi1 and MRP5. a Illustration of the putative predicted miR-128-3p binding site in the Bmi1 and MRP5 mRNA 3`-UTR region. b Spearman’s correlation analysis between Bmi1 mRNA levels and miR-128-3p levels in CRC tissues. c Spearman’s correlation analysis between MRP5 mRNA levels and miR-128-3p levels in CRC tissues. d CCK8 assay of Lv-128 transfected HCT116OxR cells in different conditions followed by oxaliplatin treatment at indicated concentrations. e Flow cytometry for apoptosis assay of Lv-128 transfected HCT116OxR cells in different conditions followed by oxaliplatin treatment (30 μM) for 24 h. f Western blot analysis of protein Bmi1, E-cad, N-cad, Vim, and Fn expression of Lv-128 transfected HCT116OxR cells in different conditions. g Migration and invasion ability of Lv-128 transfected HCT116OxR cells in different conditions were assessed by Transwell assays. h Motility ability of Lv-128 transfected HCT116OxR cells in different conditions were assayed by wound healing assays. i Western blot analysis of protein MRP5 expression of Lv-128 transfected HCT116OxR cells in different conditions. j Accumulation of Pt in Lv-128 transfected HCT116OxR cells in different conditions following exposure to 30 μM, 24 h oxaliplatin treatment. k Total Pt-DNA adduct levels in Lv-128 transfected HCT116OxR cells in different conditions following exposure to 30 μM, 24 h oxaliplatin treatment. l Immunofluorescence analysis of nuclear foci for γ-H2AX expression of Lv-128 transfected HCT116OxR cells in different conditions after 24 h oxaliplatin exposure (30 μM). Scale bars, 10 μm. m Western blot analysis of protein Bmi1 and MRP5 expression in HCT116OxR cells after incubated with indicated factors. n Immunohistochemistry analysis of Bmi1 and MRP5 protein levels in xenograft tumor tissues with intratumoral injection of NC-exo and 128-exo (20×). Results are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001